bluebird bio is a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies. The company’s objective is to develop and bring the market the most advanced products based on the transformative potential of gene therapy to provide patients hope for a better life in the face of limited or no long-term safe and effective treatment options.

bluebird bio is pushing hard on gene therapy because they believe it delivers the chance for people with severe genetic diseases and cancer to live fully, regardless of what is written in their DNA. “Our goal is to recode the science, the system – and even the status quo – for life”.


  • End-to-end manufacturing and quality data repository
  • Data sharing with internal teams and CMOs
  • Low total cost of ownership
  • FDA validatable tool


  • Comprehensive RFP win against TIBCO® Statistica™ and Discoverant with 5 months sales cycle


  • Compatible with current and future automation systems
  • Validatable / Validation kit
  • End-to-end manufacturing and quality data repository
  • Data sharing among internal teams and CMOs
  • Aggregating aphaeresis (patient), product and process characterization data
  • Low total cost of ownership
  • Skyland domain expertise / roadmap